- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cystic fibrosis
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 889KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 246KB)
Elexacaftor with tezacaftor and with ivacaftor, and ivacaftor – March 2024
Elexacaftor with Tezacaftor and with Ivacaftor, and Ivacaftor: Pack containing 56 sachets containing granules elexacaftor 100 mg with tezacaftor 50 mg and with ivacaftor 75 mg and 28 sachets containing granules ivacaftor 75 mg, Pack containing 56 sachets containing granules elexacaftor 80 mg with tezacaftor 40 mg and with ivacaftor 60 mg and 28 sachets containing granules ivacaftor 59.5 mg; Trikafta®
Last updated
30 May 2025
